We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Selenoprotein P and Non-alcoholic Fatty Liver Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01257685
First Posted: December 10, 2010
Last Update Posted: December 10, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Korea University
  Purpose

The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to steatohepatitis.

Selenoprotein P(SeP) is a secretory protein primarily produced by the liver. Previous studies demonstrated that SeP, a liver-derived secretory protein, causes insulin resistance.

Therefore, the purpose of this study is to determine the different Sep levels between healthy normal group and NAFLD group.


Condition
Non-Alcoholic Fatty Liver Disease Insulin Resistance

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Selenoprotein P and Non-alcoholic Fatty Liver Disease

Resource links provided by NLM:


Further study details as provided by Korea University:

Primary Outcome Measures:
  • Selenoprotein P

Secondary Outcome Measures:
  • DXA-measured trunk fat mass
  • CT-measured visceral fat area

Enrollment: 120
Study Start Date: September 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Control Group
NAFLD Group

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers for visiting routine medical check in our clinic
Criteria

Inclusion Criteria:

  • Healthy volunteers for visiting routine medical check in our clinic

Exclusion Criteria:

  • History of cardiovascular disease(myocardial infarction, unstable angina, or cardiovascular revascularization)
  • Diabetes
  • Hypertension
  • Malignancy
  • Severe renal or hepatic disease
  • Subjects taking medications that might affect body weight or body composition
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257685


Locations
Korea, Republic of
Hae Yoon Choi
Seoul, Korea, Republic of, 152-703
Sponsors and Collaborators
Korea University
Investigators
Study Director: Kyung Mook Choi, MD.PhD Korea University
  More Information

Responsible Party: Kyung Mook Choi, Korea university
ClinicalTrials.gov Identifier: NCT01257685     History of Changes
Other Study ID Numbers: SEPP1(NAFLD)
First Submitted: December 9, 2010
First Posted: December 10, 2010
Last Update Posted: December 10, 2010
Last Verified: December 2010

Additional relevant MeSH terms:
Insulin Resistance
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Digestive System Diseases